Incidence of adverse events similar to saline control1
- Most commonly reported treatment-emergent adverse events (≥1%) in clinical studies including randomized, double-blind, parallel-group, placebo- and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6 to 24 weeks
Incidence in which the adverse event rate is higher for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) than saline control.
*Considered to be related to progression of osteoarthritis, rather than a
treatment-related change, because appearance was nonspecific and severe joint space narrowing was
observed for both the baseline and end-of-study radiographs.
ACR=American College of Rheumatology;
KOOS QOL=Knee Injury and Osteoarthritis Outcomes Score–Quality of Life;
OA=osteoarthritis; TEAEs=treatment-emergent adverse
events;=Western Ontario and McMaster Universities Osteoarthritis Index.